Jyotsna Ghai - 02 Oct 2024 Form 4 Insider Report for Singular Genomics Systems, Inc.

Role: Chief Operating Officer
Signature: /s/ Dalen Meeter, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 02 Oct 2024
Net transactions value: $0
Form type: 4
Filing time: 03 Oct 2024, 18:00:48 UTC
Previous filing: 13 Aug 2024
Next filing: 13 Nov 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OMIC	Common Stock	Options Exercise		+1,666	+278%		2,266	02 Oct 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OMIC	Restricted Stock Units	Options Exercise		-1,666	-25%		5,000	02 Oct 2024	Common Stock	1,666		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2	On June 26, 2024, the Issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3	Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F4	25% of the RSUs vested on October 2, 2024; the remainder of the RSUs vest in 12 equal quarterly installments thereafter, beginning on January 2, 2025.